BUPRENOL DIN 02531143
Status: Marketed
Holder: CHAMPION ALSTOE ANIMAL HEALTH INC.
Health Canada record
| Active ingredient(s) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 0.3 MG |
|---|---|
| Dosage form | Solution |
| Route | Intramuscular |
| Schedule | NARCOTICS (CDSA I) |
| Class | Veterinary |
| ATC | |
| Original market date | 08-Dec-2023 |
| Current status date | 08-Dec-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Champion Alstoe Animal Health Inc. — licence 100949, not currently licensed, last inspection rating C (2023-10-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02526301 | BUPAQ | VETVIVA RICHTER GMBH | Solution | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 0.3 MG | Marketed |
| 02542536 | BUPRIXA | ZOETIS CANADA INC | Solution | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 0.3 MG | Approved |
| 02424878 | PMS-BUPRENORPHINE-NALOXONE | PHARMASCIENCE INC | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG | Marketed |
| 02424851 | PMS-BUPRENORPHINE-NALOXONE | PHARMASCIENCE INC | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG | Marketed |
| 02295695 | SUBOXONE | INDIVIOR UK LIMITED | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG | Marketed |
| 02295709 | SUBOXONE | INDIVIOR UK LIMITED | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG | Marketed |
| 02468085 | SUBOXONE | INDIVIOR UK LIMITED | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 12 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 3 MG | Marketed |
| 02468093 | SUBOXONE | INDIVIOR UK LIMITED | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 16 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 4 MG | Marketed |
| 02502313 | SUBOXONE | INDIVIOR UK LIMITED | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG; NALOXONE (NALOXONE HYDROCHLORIDE) 0.5 MG | Marketed |
| 02502321 | SUBOXONE | INDIVIOR UK LIMITED | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 4 MG; NALOXONE (NALOXONE HYDROCHLORIDE) 1 MG | Marketed |
| 02502348 | SUBOXONE | INDIVIOR UK LIMITED | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG; NALOXONE (NALOXONE HYDROCHLORIDE) 2 MG | Marketed |
| 02502356 | SUBOXONE | INDIVIOR UK LIMITED | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 12 MG; NALOXONE (NALOXONE HYDROCHLORIDE) 3 MG | Marketed |
| 02517175 | TARO-BUPRENORPHINE/NALOXONE | TARO PHARMACEUTICALS INC | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG | Approved |
| 02517183 | TARO-BUPRENORPHINE/NALOXONE | TARO PHARMACEUTICALS INC | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG | Approved |
| 02453908 | TEVA-BUPRENORPHINE/NALOXONE | TEVA CANADA LIMITED | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG | Marketed |
| 02453916 | TEVA-BUPRENORPHINE/NALOXONE | TEVA CANADA LIMITED | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG | Marketed |
| 02342510 | VETERGESIC MULTIDOSE | CEVA ANIMAL HEALTH INC | Solution | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 0.3 MG | Marketed |
| 02465256 | BELBUCA | PURDUE PHARMA | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 300 MCG | Cancelled Post Market |
| 02465272 | BELBUCA | PURDUE PHARMA | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 600 MCG | Cancelled Pre Market |
| 02465280 | BELBUCA | PURDUE PHARMA | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 750 MCG | Cancelled Pre Market |
| 02465299 | BELBUCA | PURDUE PHARMA | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 900 MCG | Cancelled Pre Market |
| 02465248 | BELBUCA | PURDUE PHARMA | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 150 MCG | Cancelled Post Market |
| 02465264 | BELBUCA | PURDUE PHARMA | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 450 MCG | Cancelled Post Market |
| 02465221 | BELBUCA | PURDUE PHARMA | Film (Soluble) | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 75 MCG | Cancelled Post Market |
| 02408104 | MYLAN-BUPRENORPHINE/NALOXONE | MYLAN PHARMACEUTICALS ULC | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG | Cancelled Post Market |
| 02408090 | MYLAN-BUPRENORPHINE/NALOXONE | MYLAN PHARMACEUTICALS ULC | Tablet | BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29038 | 2022-09-22 | Abbreviated New Drug Submission (ANDS) |